InDex Pharmaceuticals gets new patent granted in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.

Results from SWITCH Trials for Tresiba® Published in the Journal of the American Medical Association

Medicon Village companies are reaching milestones with clinical trials

International Collaboration in Cancer Innovation

24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.

20 Years anniversary medicon valley alliance

Please join us in celebrating 20 years of bringing the academia, industry, hospitals and regional government of Medicon Valley Life Science together.

Opening a new door to cell and gene therapy accessible to all

Medicon Village and Research Institutes of Sweden (RISE) invites you to explore how business models of healthcare can change based on disruptive technologies.

InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod.

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

Spago Nanomedical and Charles River Laboratories announce agreement for preclinical studies of SpagoPix

Spago Nanomedical has selected Charles River Laboratories, a leading global CRO, to conduct regulatory preclinical toxicology and safety studies of SpagoPix before clinical trials.

FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update

Novo Nordisk today announced that the US Food and Drug Administration has published the briefing documents ahead of the Advisory Committee meeting to discuss the supplemental New Drug Application for approval of Victoza injection.